Drugs / PolyIC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03732547 | Oct 2018 → Oct 2021 | hepatocellular carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02532413 | Jul 2015 → Aug 2016 | chronic hepatitis B virus infection | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Poly IC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02532413 ↗ |
| Route | Intramuscular | “Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week” NCT02532413 ↗ |